ALTAltimmune, Inc.
Pharmaceutical Preparations
- Revenue
- $41K
- 105% YoY
- Operating margin
- -230461.0%
- 55% YoY
- EBITDA
- −$94M
- 8.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$28M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired392× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $4M | −$68K | $426K | $20K | $41K | 105% |
| Operating income | −$97M | −$88M | −$96M | −$103M | −$94M | 8.4% |
| Net income | −$97M | −$85M | −$88M | −$95M | −$88M | 7.3% |
| Operating cash flow | −$78M | −$63M | −$76M | −$80M | −$68M | 15% |
| Capex | $12M | $126K | $47K | — | $11K | |
| Stock-based comp | $6M | $8M | $11M | $14M | $16M | 12% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $18K · 1
- Open-market sells, 12 mo
- $0 · 0
- Net
- $18K
Pay vs performance
No pay-versus-performance disclosure yet.